BACKGROUND: The unexpected problems at 1 of 2 US licensed manufacturers of trivalent inactivated influenza virus vaccine (TIV) in 2004 highlights the urgent need for additional vaccine sources. We evaluated a split virus TIV (Fluarix, GSK), to generate data supportive of a license application in the US. METHODS:Healthy adults ages 18-64 years at four centers were randomly assigned to receive a single IM injection of Fluarix (n = 763) or placebo (n = 193) in double-blind fashion. Subjects were monitored for safety and serum hemagglutination-inhibition (HAI) titers determined before and 21 days after vaccination. RESULTS:Vaccine was well tolerated, with only mild to moderate myalgias and injection site pain and redness being more common in vaccine than placebo recipients. Four-fold or greater increases in serum HAI titers were seen in 60%, 62% and 78% of vaccine recipients against the H1, H3, and B components of the vaccine, respectively, and post-vaccination titers of > 1:40 achieved in 98%, 99% and 99% of subjects, exceeding the prespecified criteria for acceptability for all three antigens. CONCLUSIONS:Fluarix has a safety and immunogenicity profile like other US-licensed inactivated influenza vaccines and should be effective when used to immunize US adults. SUMMARY LINE: The results of this study were pivotal for the rapid approval of Fluarix in the US for use in adults 18 years of age or older.
RCT Entities:
BACKGROUND: The unexpected problems at 1 of 2 US licensed manufacturers of trivalent inactivated influenza virus vaccine (TIV) in 2004 highlights the urgent need for additional vaccine sources. We evaluated a split virus TIV (Fluarix, GSK), to generate data supportive of a license application in the US. METHODS: Healthy adults ages 18-64 years at four centers were randomly assigned to receive a single IM injection of Fluarix (n = 763) or placebo (n = 193) in double-blind fashion. Subjects were monitored for safety and serum hemagglutination-inhibition (HAI) titers determined before and 21 days after vaccination. RESULTS: Vaccine was well tolerated, with only mild to moderate myalgias and injection site pain and redness being more common in vaccine than placebo recipients. Four-fold or greater increases in serum HAI titers were seen in 60%, 62% and 78% of vaccine recipients against the H1, H3, and B components of the vaccine, respectively, and post-vaccination titers of > 1:40 achieved in 98%, 99% and 99% of subjects, exceeding the prespecified criteria for acceptability for all three antigens. CONCLUSIONS: Fluarix has a safety and immunogenicity profile like other US-licensed inactivated influenza vaccines and should be effective when used to immunize US adults. SUMMARY LINE: The results of this study were pivotal for the rapid approval of Fluarix in the US for use in adults 18 years of age or older.
Authors: H Keipp Talbot; Wendy Keitel; Thomas R Cate; John Treanor; James Campbell; Rebecca C Brady; Irene Graham; Cornelia L Dekker; Dora Ho; Patricia Winokur; Emmanuel Walter; Jillian Bennet; Neil Formica; Gunter Hartel; Maryanne Skeljo; Kathryn M Edwards Journal: Vaccine Date: 2008-06-02 Impact factor: 3.641
Authors: James D Campbell; Christopher V Chambers; Rebecca C Brady; Michael C Caldwell; Nathan L Bennett; Marc A Fourneau; Varsha K Jain; Bruce L Innis Journal: Hum Vaccin Date: 2011-01-01
Authors: Jessica C Seidman; Stephanie A Richard; Cécile Viboud; Mark A Miller Journal: Influenza Other Respir Viruses Date: 2011-06-13 Impact factor: 4.380
Authors: Noris Pavia-Ruz; Miguel Angel Rodriguez Weber; Yu-Lung Lau; E Anthony S Nelson; Angkool Kerdpanich; Li-Min Huang; Peter Silas; Paul Qaqundah; Mark Blatter; Robert Jeanfreau; Paul Lei; Varsha Jain; Mohamed El Idrissi; Yang Feng; Bruce Innis; Mathieu Peeters; Jeanne-Marie Devaster Journal: Hum Vaccin Immunother Date: 2013-06-19 Impact factor: 3.452